Cargando…

Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States

BACKGROUND: Little data exist on how opioid doses vary with the length of exposure among chronic opioid users. METHODS: To characterize the change in the dosage of opioids over time, a retrospective cohort study using the PharMetrics database for the years 1999 through 2008 was conducted. Individual...

Descripción completa

Detalles Bibliográficos
Autores principales: Cepeda, Maria Soledad, Etropolski, Mila, Weinstein, Rachel, Fife, Daniel, Boston, Raymond, Matcho, Amy
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905346/
https://www.ncbi.nlm.nih.gov/pubmed/20565876
http://dx.doi.org/10.1186/1472-684X-9-14
_version_ 1782183950565769216
author Cepeda, Maria Soledad
Etropolski, Mila
Weinstein, Rachel
Fife, Daniel
Boston, Raymond
Matcho, Amy
author_facet Cepeda, Maria Soledad
Etropolski, Mila
Weinstein, Rachel
Fife, Daniel
Boston, Raymond
Matcho, Amy
author_sort Cepeda, Maria Soledad
collection PubMed
description BACKGROUND: Little data exist on how opioid doses vary with the length of exposure among chronic opioid users. METHODS: To characterize the change in the dosage of opioids over time, a retrospective cohort study using the PharMetrics database for the years 1999 through 2008 was conducted. Individuals exposed to opioids in 2000 who had 2 opioid dispensings at least 6 months apart and were opioid naive (did not receive any opioid 6 month before their exposure in 2000) were included. The date of the first dispensing in 2000 was defined as the index date and the dispensing had to be for a strong and full agonist opioid. All opioid doses were converted to oral morphine equivalent doses. Exposure was classified as continuous or intermittent. Mean, median, interquartile range, and 95(th )percentile of opioid dose over 6-month periods, as well as the percentage of subjects who ever received a high or very high opioid dose, were calculated. RESULTS: Among the 48,986 subjects, the mean age was 44.5 years and 54.5% were women. Intermittent exposure was observed in 99% of subjects; continuous exposure was observed in 1% of subjects. The mean duration of exposure for the subjects who were continuously exposed to opioids was 477 days. In subjects with no cancer diagnosis who were continuously exposed to opioids, the mean, 25(th), 50(th), and 75(th )percentile of dose was stable during the first 2 years of use, but the 95(th )percentile increased. Seven percent of them were exposed to doses of 180 mg or more of morphine at some point. CONCLUSIONS: Dose escalation is uncommon in subjects with intermittent exposure to opioids. For subjects with continuous exposure to opioids who have cancer, doses rise substantially with time. For those without cancer, doses remain relatively stable for the first 2 years of use, but subsequently increase. Seven percent of subjects with no cancer diagnosis will be exposed to daily doses of 180 mg or more of morphine equivalent at some point.
format Text
id pubmed-2905346
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29053462010-07-17 Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States Cepeda, Maria Soledad Etropolski, Mila Weinstein, Rachel Fife, Daniel Boston, Raymond Matcho, Amy BMC Palliat Care Research Article BACKGROUND: Little data exist on how opioid doses vary with the length of exposure among chronic opioid users. METHODS: To characterize the change in the dosage of opioids over time, a retrospective cohort study using the PharMetrics database for the years 1999 through 2008 was conducted. Individuals exposed to opioids in 2000 who had 2 opioid dispensings at least 6 months apart and were opioid naive (did not receive any opioid 6 month before their exposure in 2000) were included. The date of the first dispensing in 2000 was defined as the index date and the dispensing had to be for a strong and full agonist opioid. All opioid doses were converted to oral morphine equivalent doses. Exposure was classified as continuous or intermittent. Mean, median, interquartile range, and 95(th )percentile of opioid dose over 6-month periods, as well as the percentage of subjects who ever received a high or very high opioid dose, were calculated. RESULTS: Among the 48,986 subjects, the mean age was 44.5 years and 54.5% were women. Intermittent exposure was observed in 99% of subjects; continuous exposure was observed in 1% of subjects. The mean duration of exposure for the subjects who were continuously exposed to opioids was 477 days. In subjects with no cancer diagnosis who were continuously exposed to opioids, the mean, 25(th), 50(th), and 75(th )percentile of dose was stable during the first 2 years of use, but the 95(th )percentile increased. Seven percent of them were exposed to doses of 180 mg or more of morphine at some point. CONCLUSIONS: Dose escalation is uncommon in subjects with intermittent exposure to opioids. For subjects with continuous exposure to opioids who have cancer, doses rise substantially with time. For those without cancer, doses remain relatively stable for the first 2 years of use, but subsequently increase. Seven percent of subjects with no cancer diagnosis will be exposed to daily doses of 180 mg or more of morphine equivalent at some point. BioMed Central 2010-06-18 /pmc/articles/PMC2905346/ /pubmed/20565876 http://dx.doi.org/10.1186/1472-684X-9-14 Text en Copyright ©2010 Cepeda et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Cepeda, Maria Soledad
Etropolski, Mila
Weinstein, Rachel
Fife, Daniel
Boston, Raymond
Matcho, Amy
Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States
title Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States
title_full Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States
title_fullStr Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States
title_full_unstemmed Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States
title_short Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States
title_sort dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the united states
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905346/
https://www.ncbi.nlm.nih.gov/pubmed/20565876
http://dx.doi.org/10.1186/1472-684X-9-14
work_keys_str_mv AT cepedamariasoledad dosepatternsincommerciallyinsuredsubjectschronicallyexposedtoopioidsalargecohortstudyintheunitedstates
AT etropolskimila dosepatternsincommerciallyinsuredsubjectschronicallyexposedtoopioidsalargecohortstudyintheunitedstates
AT weinsteinrachel dosepatternsincommerciallyinsuredsubjectschronicallyexposedtoopioidsalargecohortstudyintheunitedstates
AT fifedaniel dosepatternsincommerciallyinsuredsubjectschronicallyexposedtoopioidsalargecohortstudyintheunitedstates
AT bostonraymond dosepatternsincommerciallyinsuredsubjectschronicallyexposedtoopioidsalargecohortstudyintheunitedstates
AT matchoamy dosepatternsincommerciallyinsuredsubjectschronicallyexposedtoopioidsalargecohortstudyintheunitedstates